- Type / Class
- Equity / Common Stock
- Shares outstanding
- 61,152,075
- Total 13F shares
- 23,269,447
- Share change
- +2,893,015
- Total reported value
- $646,000,000
- Price per share
- $27.76
- Number of holders
- 34
- Value change
- +$80,276,736
- Number of buys
- 20
- Number of sells
- 13
Quarterly Holders Quick Answers
What is CUSIP 04351P101?
CUSIP 04351P101 identifies ASND - Ascendis Pharma A/S - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 04351P101:
Top shareholders of ASND - Ascendis Pharma A/S - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
8.8%
|
5,409,990
|
$151,480,000 | — | 31 Mar 2017 | |
| FMR LLC |
13F
|
Company |
5.3%
|
3,238,720
|
$90,685,000 | — | 31 Mar 2017 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
4.4%
|
2,717,315
|
$76,085,000 | — | 31 Mar 2017 | |
| Vivo Capital, LLC |
13F
|
Company |
2.9%
|
1,766,832
|
$49,471,000 | — | 31 Mar 2017 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
2.2%
|
1,351,463
|
$37,841,000 | — | 31 Mar 2017 | |
| EcoR1 Capital, LLC |
13F
|
Company |
1.7%
|
1,025,700
|
$28,720,000 | — | 31 Mar 2017 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
1.5%
|
929,226
|
$26,018,000 | — | 31 Mar 2017 | |
| VHCP Management II, LLC |
13F
|
Company |
1.3%
|
811,492
|
$22,722,000 | — | 31 Mar 2017 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
1.1%
|
700,924
|
$19,626,000 | — | 31 Mar 2017 | |
| JANUS HENDERSON INVESTORS US LLC |
13F
|
Company |
0.91%
|
559,035
|
$15,653,000 | — | 31 Mar 2017 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.9%
|
550,000
|
$15,400,000 | — | 31 Mar 2017 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.53%
|
325,000
|
$9,100,000 | — | 31 Mar 2017 | |
| OppenheimerFunds, Inc. |
13F
|
Company |
0.49%
|
297,630
|
$8,334,000 | — | 31 Mar 2017 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.42%
|
255,455
|
$7,153,000 | — | 31 Mar 2017 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.4%
|
246,100
|
$6,891,000 | — | 31 Mar 2017 | |
| Marshall Wace North America L.P. |
13F
|
Company |
0.29%
|
179,355
|
$5,022,000 | — | 31 Mar 2017 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.23%
|
138,383
|
$3,875,000 | — | 31 Mar 2017 | |
| Cormorant Asset Management, LP |
13F
|
Company |
0.16%
|
100,000
|
$2,800,000 | — | 31 Mar 2017 | |
| Foresite Capital Management III, LLC |
13F
|
Company |
0.16%
|
100,000
|
$2,800,000 | — | 31 Mar 2017 | |
| EMORY UNIVERSITY |
13F
|
Company |
0.14%
|
83,411
|
$2,336,000 | — | 31 Mar 2017 | |
| ALPS ADVISORS INC |
13F
|
Company |
0.04%
|
27,120
|
$759,000 | — | 31 Mar 2017 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.03%
|
18,214
|
$510,000 | — | 31 Mar 2017 | |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.02%
|
15,000
|
$420,000 | — | 31 Mar 2017 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.02%
|
14,817
|
$414,000 | — | 31 Mar 2017 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
10,236
|
$287,000 | — | 31 Mar 2017 | |
| Aperio Group, LLC |
13F
|
Company |
0.01%
|
7,242
|
$203,000 | — | 31 Mar 2017 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
5,345
|
$150,000 | — | 31 Mar 2017 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.01%
|
5,158
|
$144,000 | — | 31 Mar 2017 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.01%
|
5,100
|
$143,000 | — | 31 Mar 2017 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0%
|
1,994
|
$56,000 | — | 31 Mar 2017 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
1,133
|
$32,000 | — | 31 Mar 2017 | |
| UBS Group AG |
13F
|
Company |
0%
|
959
|
$27,000 | — | 31 Mar 2017 | |
| Creative Planning |
13F
|
Company |
0%
|
350
|
$10,000 | — | 31 Mar 2017 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0%
|
100
|
$2,000 | — | 31 Mar 2017 | |
| US BANCORP \DE\ |
13F
|
Company |
0%
|
76
|
$2,000 | — | 31 Mar 2017 |
Institutional Holders of Ascendis Pharma A/S - Common Stock (ASND) as of Q2 2017
As of 30 Jun 2017,
Ascendis Pharma A/S - Common Stock (ASND) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
23,269,447 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, LLC, ORBIMED ADVISORS LLC, FMR LLC, Vivo Capital, LLC, BAKER BROS. ADVISORS LP, EcoR1 Capital, LLC, venBio Select Advisor LLC, VHCP Management II, LLC, ACUTA CAPITAL PARTNERS, LLC, and EVENTIDE ASSET MANAGEMENT, LLC.
This page lists
34
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2017 vs Q1 2017 Across Filers
Q1 2017 holders
34
Q2 2017 holders
34
Holder diff
0
| Investor | Q1 2017 Shares | Q2 2017 Shares | Share Diff | Share Chg % | Q1 2017 Value $ | Q2 2017 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.